PTEN: A Multifaceted Tumor Suppressor
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (15 June 2019) | Viewed by 97029
Special Issue Editors
Interests: PTEN; biomarkers; targeted therapy; molecular biology
Interests: methodology of clinical trials; biomarker clinical validation; meta-analyses
Special Issue Information
Dear Colleagues,
PTEN is the main negative regulator of PI3K pathway. PTEN levels and/or function can be regulated through multiple mechanisms (e.g., epigenetic silencing, post-translational modifications, etc.), and its protein and lipid phosphatase activity is involved in different cell functions, such as survival, growth, DNA repair, and protein synthesis. Its function is determined, at least in part, by its subcellular localization and a longer PTEN variant, named PTEN long, which may be implicated in paracrine cell-cell communication.
Germline loss of PTEN expression/function results in hereditary cancer predisposition syndromes, clinically referred to as PTEN hamartoma syndromes (PHTS) or PTENopaties, which carry a high lifetime risk of developing either benign or malignant growth in different target organs. Moreover, somatic PTEN aberrations are frequently observed in a wide spectrum of sporadic cancers, such as glioblastoma multiforme, malignant melanoma, endometrial, prostate, breast, colorectal, and lung cancers. Indeed, PTEN is a haploinsufficient tumor suppressor, and even subtle reductions in its active levels dictate cancer susceptibility in a dose-dependent manner.
In this Special Issue, we will focus on the mechanisms regulating PTEN expression and function, as well as on its functional role in PTENopaties and cancer, highlighting its prognostic/predictive potential and examining possible strategies to target PTEN-deficient tumors.
Dr. Ludovica Ciuffreda
Dr. Emilio Bria
Dr. Robert Pilarski
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- PTEN
- hereditary syndrome
- hereditary cancer
- biomarker clinical validation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.